{"analyses":[{"ciLowerLimit":"0.50","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.97","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0175","pValueComment":"2-sided p-value","paramType":"Hazard Ratio (HR)","paramValue":"0.69","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"57"}],"title":"Died"},{"measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"21"}],"title":"Alive at data cut-off"},{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"5"}],"title":"Terminated prior to death (withdrawn consent)"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"description":"Number of Participants with Overall Survival (OS) - Cohort A only.","groups":[{"description":"2x150mg film-coated tablets","id":"OG000","title":"Cohort A Olaparib 300mg bd"},{"description":"either enzalutamide capsules (160 mg od) or abiraterone acetate tablets (1,000 mg od with 5 mg bid prednisone)","id":"OG001","title":"Cohort A Investigators Choice of NHA"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"Approximately 35 months after the first patient was randomised.","title":"Overall Survival (OS) - Cohort A Only","type":"SECONDARY","unitOfMeasure":"Participants"}